Conolidine’s analgesic effects stem from its interaction with non-opioid pain pathways. Contrary to opioids, which bind to µ-opioid receptors in the central anxious program, conolidine modulates alternate molecular targets. A Science Innovations research discovered that conolidine interacts with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. By https://danielc206euk2.wikinewspaper.com/user